https://orcid.org/0000-0002-0981-847X
Figures
Abstract
Background
The purpose of this study was to clarify the practical clinical treatment for acute carbon monoxide (CO) poisoning in Japan and to investigate the efficacy of hyperbaric oxygen (HBO2) therapy in preventing delayed neurological sequelae (DNS) in the acute phase of CO poisoning.
Methods
We conducted a multicenter, prospective, observational study of acute CO poisoning in Japan. Patients with acute CO poisoning were enrolled and their treatment details were recorded. The primary endpoint was the onset of DNS within 2 months of CO exposure. Factors associated with DNS were assessed with logistic regression analysis.
Results
A total of 311 patients from 57 institutions were registered and 255 were analyzed: 171 received HBO2 therapy (HBO2 group) and 84 did not (normobaric oxygen [NBO2] group). HBO2 therapy was performed zero, once, twice, or three times within the first 24 h in 1.8%, 55.9%, 30.9%, and 11.3% of the HBO2 group, respectively. The treatment pressure in the first HBO2 session was 2.8 ATA (47.9% of the HBO2 group), 2.0 ATA (41.8%), 2.5 ATA (7.9%), or another pressure (2.4%). The incidence of DNS was 13/171 (7.6%) in the HBO2 group and 3/84 (3.6%) in the NBO2 group (P = 0.212). The number of HBO2 sessions in the first 24 h was one of the factors associated with the incidence of DNS (odds ratio, 2.082; 95% confidence interval, 1.101–3.937; P = 0.024).
Conclusions
The practical clinical treatment for acute CO poisoning, including HBO2 therapy, varied among the institutions participating in Japan. HBO2 therapy with inconsistent protocols showed no advantage over NBO2 therapy in preventing DNS. Multiple HBO2 sessions was associated with the incidence of DNS.
Citation: Fujita M, Todani M, Kaneda K, Suzuki S, Wakai S, Kikuta S, et al. (2021) Use of hyperbaric oxygen therapy for preventing delayed neurological sequelae in patients with carbon monoxide poisoning: A multicenter, prospective, observational study in Japan. PLoS ONE 16(6): e0253602. https://doi.org/10.1371/journal.pone.0253602
Editor: Tai-Heng Chen, Kaohsuing Medical University Hospital, TAIWAN
Received: November 21, 2020; Accepted: June 8, 2021; Published: June 18, 2021
Copyright: © 2021 Fujita et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Hyperbaric oxygen (HBO2) therapy is thought to be essential for preventing neurological sequelae in patients with carbon monoxide (CO) poisoning, based on the results of a randomized controlled trial (RCT) reported by Weaver et al. [1]. However, the results of RCTs, including subsequent reports, have been conflicting [2–6], and the effects of HBO2 therapy for patients with CO poisoning remains contentious. A previous meta-analysis did not find beneficial effects of HBO2 therapy or the reduction of adverse neurological outcomes by HBO2 therapy for CO poisoning [7]. Therefore, it is unclear whether HBO2 therapy in the acute phase of CO poisoning prevents neurological sequelae.
Our previous survey, performed by questionnaire, showed that the clinical practice of HBO2 therapy for CO poisoning varied in both its indications and the practice regimens used in Japan [8]. This situation is not specific to Japan and has also been reported in the USA and Europe [9, 10]. These findings suggest that there is no clear clinical consensus about HBO2 therapy for acute CO poisoning. Therefore, we conducted a multicenter, prospective, observational study of acute CO poisoning to clarify the practical clinical treatment for acute CO poisoning in Japan and to investigate the efficacy of HBO2 therapy in preventing DNS in the acute phase of CO poisoning.
Methods
Design and setting
We conducted a multicenter, prospective, observational study of acute CO poisoning in Japan called the COP-J Study to clarify the efficacy of HBO2 therapy in the acute phase of CO poisoning. A cohort of patients with acute CO poisoning from 54 institutions was enrolled in the COP-J Study, which recorded the patients’ data after approval was given by the Ethics Committee of each institution. The COP-J Study was approved by the Japanese Society of Intensive Care Medicine (No. 0011). The therapeutic policies of the majority of these institutions have already been reported [8] and 19 (35.2%) of the 54 institutions involved in this study did not administer HBO2 therapy and performed only normobaric oxygen (NBO2) therapy. The 35 enrolled institutions that had an HBO2 chamber administered HBO2 therapy according to their institutional policies [8]. At the start of the study, there were 568 institutions in Japan that had an HBO2 chamber, of which 115 had a board-certified fellow of the Japanese Society of Hyperbaric and Undersea Medicine.
Data collection and analysis
Patients diagnosed with acute CO poisoning based on any symptoms after CO exposure or on a carboxyhemoglobin (COHb) level exceeding 10%, between October 2015 and September 2018, were enrolled in the study. The medical records of the patients, including the circumstances of CO exposure, prehospital information, physical and laboratory findings upon arrival, and details of treatments, including HBO2 therapy, were recorded by the University Hospital Medical Information Network–Internet Data and Information Center for Medical Research (UMIN–INDICE) web system. The primary endpoint was the onset of delayed neurological sequelae (DNS) within 2 months of CO exposure. DNS was defined as cognitive dysfunction that affected daily life after an improvement in disturbed consciousness. DNS was checked at outpatient consultations or by telephone if the patient did not visit the hospital. In the telephone consultation for DNS, the physician addressed the following questions to the patients or their family: “Is there any hindrance to daily life?”; “Do you have memory problems?”; “Is there any change in your personality?”; “Are there more things you cannot do compared with before?”, and so on. If there was any doubt about the presence of DNS, the physician instructed the patient to visit the hospital. DNS was finally diagnosed by a physician based on all the findings at the time of diagnosis, including results of a cognitive function test, such as the mini-mental state examination, the Wechsler adult intelligence scale, Hasegawa’s dementia scale-revised [11], the trail-making test, or the story recall test. In addition, the physicians were not blinded as to the treatment of acute CO poisoning. The secondary endpoint was the improvement in prolonged consciousness disturbance (PCD), which was defined as prolonged consciousness disturbance after 24 h from admission. The improvement in PCD was checked by a physician at discharge or at 2 months after CO exposure. Before the analysis, we excluded patients with cardiopulmonary arrest upon arrival, or in-hospital death, or who were lost to follow-up. In the analysis, we compared the incidence of DNS and improvement in PCD between patients who received either HBO2 or NBO2 therapy during the acute phase. The factors associated with DNS and unimproved PCD were also identified.
Statistical analyses
Variables are shown as means ± standard deviations or numbers (percentages). Missing values were excluded from all analyses. Univariate analyses were performed with a t test for continuous variables and a χ2 test for categorical variables. Univariate regression and multivariable logistic regression with the stepwise variable selection method were performed to identify factors associated with DNS and unimproved PCD, and the results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). The factors associated with DNS and unimproved PCD in previous reports [12–17] were included as variables in the multivariable logistic regression models. Values of P < 0.05 were considered to indicate statistical significance. All analyses were performed with IBM SPSS Statistics for Windows version 22 (IBM SPSS Inc., Chicago, IL).
Results
Patients’ characteristics
A total of 311 patients from 54 institutions were registered and 255 were included in the analysis (Fig 1). Of the patients included, 171 received HBO2 therapy (HBO2 group) and 84 did not (NBO2 group). Patients excluded from the analyses included 12 with cardiopulmonary arrest on arrival (CPAOA), three who died in hospital, and 41 who were lost to follow-up.
HBO2, hyperbaric oxygen; NBO2, normobaric oxygen; CPAOA, cardiopulmonary arrest on arrival.
The patients’ characteristics and the physiological and laboratory findings on arrival are shown in Table 1. The mean age was 54 ± 22 years in the NBO2 group and 49 ± 19 years in the HBO2 group (P = 0.063). Almost 60% of the patients were male and half the patients had a history of smoking. The sex ratios and smoking histories did not differ significantly between the NBO2 and HBO2 groups. The total rate of patients who had attempted suicide was 29.8% and the difference between the NBO2 and HBO2 groups was not significant (25.0% vs 32.2%, respectively; P = 0.240). In more than half the patients in both groups, CO poisoning was caused by burning charcoal. In the NBO2 group, the number of cases caused by fires was greater than in the HBO2 group, whereas the number of cases caused by car exhausts was lower. The environmental circumstances of CO exposure was the same in both groups. Almost all the patients arrived at hospital by ambulance and the incidence of loss of consciousness was the same in the NBO2 and HBO2 groups (42.3% vs 48.0%, respectively, P = 0.413). Oxygen was administered by the emergency medical service slightly less frequently in the NBO2 group than in the HBO2 group (84.2% vs 92.4%, respectively; P = 0.064). The estimated time of exposure to CO was 181 ± 376 min in the NBO2 group and 202 ± 256 min in the HBO2 group, and the difference was not significant (P = 0.605). The time from CO exposure to hospitalization was the same between the NBO2 and HBO2 groups (240 ± 382 and 279 ± 350 min, respectively; P = 0.420). In the NBO2 group, 47 (56.0%) patients were transferred to an institution that offered only NBO2 therapy by EMS.
In the arterial blood gas analyses, PaO2 was significantly lower in the NBO2 group than in the HBO2 group (198 ± 103 vs 270 ± 122 Torr, respectively; P < 0.001) and lactic acidosis was significantly more severe in the NBO2 group than in the HBO2 group. There was no significant difference in COHb levels between the NBO2 and HBO2 groups (19.3 ± 10.2% and 18.7 ± 11.4%, respectively; P = 0.682). Furthermore, in the NBO2 group, the COHb levels were 20.9 ± 10.0% in patients who were transferred to institutions that only offered NBO2 therapy and 17.2 ± 10.1% in patients transferred to institutions that also provided HBO2 therapy (P = 0.101).
Treatment regimens including HBO2 therapy and NBO2 therapy
The number of HBO2 sessions during the first 24 h and the first week in the HBO2 group are shown in Fig 2. HBO2 therapy was performed zero, one, two, or three times within the first 24 h in 1.8%, 55.9%, 30.9%, and 11.3% of the HBO2 group, respectively. In the HBO2 group, 30 patients (17.9% of the group) received HBO2 therapy only once during the first week after admission; 49 patients (29.2% of the HBO2 group) received HBO2 therapy three times in the first week; and the maximum number of treatments during the first week was 15. The average time from arrival to the first HBO2 session was 158 ± 147 min among the patients who were administered HBO2 therapy on the first day.
The treatment pressures in each HBO2 session during the first 24 h are shown in Table 2. The treatment pressure in the first HBO2 session was 2.8 atmospheres absolute (ATA) (47.9% of the HBO2 group), 2.0 ATA (41.8%), 2.5 ATA (7.9%), or another pressure (2.4%). A treatment pressure of 2.0 ATA was used in the majority of patients in both the second and third HBO2 sessions. In addition, HBO2 therapy were not administered during the first 24 h in 2 patients of the HBO2 group and the details of HBO2 therapy were unknown in 4 patents.
The number of patients treated with mechanical ventilation was significantly more in the NBO2 group than in the HBO2 group (25.0% vs 4.7%, respectively, P < 0.001; Table 3). The period of oxygen administration during the hospital stay was 344 ± 2128 h and 70 ± 190 h in the NBO2 and HBO2 groups, respectively, which did not differ significantly (P = 0.266; Table 3). ICU days was also significantly longer in the NBO2 group than in the HBO2 groups (4.1 ± 11.0 and 1.3 ± 2.4 days, respectively; P = 0.025; Table 3), but hospital days did not differ between the groups (P = 0.294; Table 3).
Incidence of DNS, improvement in PCD, and factors associated with DNS and unimproved PCD
The total incidence of DNS was 16/255 (6.3%) in this study, and did not differ between the NBO2 group and the HBO2 group (3.6% vs 7.6%, respectively; P = 0.212, Table 3). The total incidences of PCD and unimproved PCD were 19/255 (7.5%) and 8/255 (3.1%), respectively. Neither of these measures differed between the NBO2 group and the HBO2 group (PCD: 6.0% vs 8.2%, respectively, P = 0.523; unimproved PCD: 2.4% vs 3.5%, respectively, P = 0.627; Table 3).
Concerning the association between the number of HBO2 sessions in the first 24 h and the incidence of DNS, a greater number of HBO2 sessions in the first 24 h was associated with a greater incidence of DNS (P = 0.020; Table 4). The incidence of unimproved PCD was not associated with the number of HBO2 sessions in the first 24 h (P = 0.735; Table 4).
The treatment pressures in the first HBO2 session were 2.8 ATA (n = 7), 2.5 ATA (n = 1), and 2.0 ATA (n = 4) in the DNS patients in the HBO2 group, and 2.8 ATA (n = 6) and 2.0 ATA (n = 1) in the unimproved PCD patients in the HBO2 group.
Among 35 patients with abnormal findings in CT or MRI, DNS was observed in 2 (22.2%) and 8 (30.8%) patients in the NBO2 group (n = 9) and the HBO2 group (n = 26), respectively. There was no significant difference in the incidence of DNS between the groups (P = 0.625). Unimproved PCD was observed in 2 (22.2%) and 6 (23.1%) patients in the NBO2 group and the HBO2 group, respectively. There was no significant difference between the groups (P = 0.958).
The following variables, previously reported to be associated with DNS and unimproved PCD [12–17], were included in the univariate and multivariable logistic regression models to identify factors associated with the incidence of DNS and unimproved PCD: age, sex, type of CO poisoning, cause, consciousness loss at the scene, estimated exposure time, time from exposure to hospital, Glasgow Coma Scale (GCS) score on arrival, COHb, lactate level, white blood cell count, and number of HBO2 sessions and maximum therapeutic pressure in the first 24 h.
In the univariate regression analysis for the incidence of DNS, type of CO poisoning (intentional), cause (charcoal), consciousness loss at the scene, estimated exposure time, time from exposure to hospital, GCS score on arrival, white blood cell count, and number of HBO2 sessions in the first 24 h were statistically significant (Table 5). The exposure time (OR, 1.003; 95% CI, 1.001–1.004; P < 0.001), GCS score (OR, 0.803; 95% CI, 0.695–0.927; P = 0.003), and the number of HBO2 sessions in the first 24 h (OR, 2.082; 95% CI, 1.101–3.937; P = 0.024) were independently associated with the incidence of DNS in the multivariable logistic regression model (Table 5).
In the univariate regression analysis for unimproved PCD, estimated exposure time, time from exposure to hospitalization, and GCS score on arrival were statistically significant (Table 6). The time from exposure to hospital (OR, 1.002; 95% CI, 1.001–1.004; P = 0.007) was independently associated with unimproved PCD in the multivariable logistic regression model (Table 6).
Discussion
In this study, it has been shown that the clinical practice for acute CO poisoning varies in Japan, and that the application of and protocols for HBO2 therapy are not consistent. HBO2 therapy with inconsistent protocols showed no advantage over NBO2 therapy in preventing DNS and unimproved PCD. Furthermore, a greater number of HBO2 sessions in the first 24 h was associated with a higher incidence of DNS.
In clinical practice, the treatment for acute CO poisoning, including HBO2 therapy, varied in the present study, as in our previous report [8]. In particular, the profiles of HBO2 therapy, including the number of treatments given and the therapeutic pressures used, were not consistent. These results are similar to reports from Europe and the USA [9, 10], and may indicate that there is no global consensus on an effective regimen of HBO2 therapy for CO poisoning. Further research, including RCTs, is required to establish consensus on these issues.
In the present study, the total incidence of DNS was only 6.3%, which is lower than that in other studies [1–6]. In our study, all of the patients with any symptoms after CO exposure or with a COHb level exceeding 10% were registered and analyzed, except for 12 CPAOA patients and three patients who died in hospital (Fig 1). The patients in this study might have had milder conditions than those in other studies because the entry criteria were less restrictive. Furthermore, in this study, DNS was only defined as cognitive dysfunction that affected daily life after an improvement in disturbed consciousness and did not include minor symptoms, such as tinnitus or headache. Therefore, patients with mild symptoms or with symptoms other than cognitive dysfunction were not included. Furthermore, 40% of the patients without DNS were only diagnosed by telephone, so patients with mild symptoms might have been overlooked. These aspects of our study may have influenced the lower incidence of DNS.
Although the protocol for HBO2 therapy varied, incidences of DNS and unimproved PCD did not differ between the patients treated with NBO2 only and those treated with HBO2, and the incidence of DNS tended to be lower in patients treated with NBO2 only than in those treated with HBO2 in this study (Table 3). Many RCTs have tried to clarify the efficacy of HBO2 therapy in preventing DNS after CO poisoning [1–6], and half of them have shown no beneficial effects of HBO2 therapy in this context [2, 3, 6]. In contrast, several reports have claimed that therapeutic pressure less than 2.5 ATA does not produce the beneficial effects of HBO2 therapy [18, 19]. Thom et al. reported that the adherence of activated neutrophils, which is one of the mechanisms underlying the development of DNS after CO poisoning, was suppressed experimentally at 2.5 or 3.0 ATA, but not at 2.0 ATA [18]. The therapeutic pressures in the RCTs that demonstrated the beneficial effects of HBO2 therapy exceeded 2.5 ATA [1, 4, 5, 20]. Birmingham and Hoffman claimed that inadequate pressure during HBO2 therapy may only enhance oxygen toxicity, without the benefit offered by HBO2 at higher pressures [19]. In the present study, only 60% of the patients in the HBO2 group were administered the first session of HBO2 therapy at pressures of more than 2.5 ATA (Table 2) and the same rate was observed in the DNS patients treated with HBO2 therapy at pressures of more than 2.5 ATA. Therefore, in this study, insufficient treatment pressure might also have affected the number of patients with DNS.
Oxidative stress is a key mechanism in DNS [20–25]. HBO2 reduced oxidative stress in an animal model of CO poisoning [26] and its beneficial effects included inhibition of leukocyte beta-2 integrins [18], reversal of CO-cytochrome c oxidase binding [27], and recovery of energy metabolism [28]. However, there have been reports that HBO2 therapy itself induces oxidative stress [29–32]. Experimental data have shown that HBO2 induces oxidative stress in healthy rat brains, measured as the lipid peroxidation products in brain cortex homogenates [29–31]. This HBO2-induced oxidative stress is related to the HBO2 pressure [29] or the exposure time [30]. It has also been reported that a single session of HBO2 (2.4 kPa, 131 min) reduced plasma vitamin C and increased plasma lipid peroxides and urinary 8-oxo-deoxyguanosine excretion in healthy volunteers [32]. Although HBO2 therapy has beneficial effects, it should be considered that there are concerns about adverse effects of HBO2 therapy such as HBO2-induced oxidative stress.
A greater number of HBO2 sessions in the first 24 h was associated with a higher incidence of DNS (Tables 4 and 5). Two RCTs have reported that two HBO2 sessions at 2.0 ATA were neither more beneficial nor more harmful than one session [2, 3], although multiple HBO2 sessions at 2.5 to 2.8 ATA had beneficial effects on preventing DNS [1, 4, 5]. Annane et al. [2] reported that two HBO2 sessions at 2.0 ATA were associated with worse outcomes than one HBO2 session in comatose patients with acute CO poisoning, and that there was no evidence of the superiority of HBO2 over NBO2 in patients with transient loss of consciousness. Raphael et al. [3] reported that two of HBO2 sessions at 2.0 ATA showed no beneficial effects versus one session in patients with CO poisoning who experienced sustained loss of consciousness. Further, one HBO2 session was also ineffective versus NBO2 therapy in patients who did not experience sustained loss of consciousness [3]. A recent meta-analysis of the therapeutic effects of different numbers of HBO2 sessions found that HBO2 therapy at a therapeutic pressure of 2.0 ATA was associated with a lower risk of memory impairment than NBO2 therapy, but that two HBO2 sessions was associated with a higher risk of memory impairment than one session [33]. However, as mentioned above, the therapeutic pressure of 2.0 ATA was considered to be insufficient to produce its beneficial effects [19]. Therefore, multiple HBO2 sessions with insufficient therapeutic pressure should be administered cautiously because of the possibility of worsening symptoms. However, the present data could not rule out the possibility that more severely affected patients had received more HBO2 sessions because the HBO2 therapy protocols were not consistent and depended on each institutions’ policies [8].
In the present study, abnormal CT or MRI findings tended to be less frequent in the NBO2 group than in the HBO2 group, although the amount of data obtained was limited (Table 2). Previous studies have reported that imaging abnormalities are a risk factor for DNS [34, 35]. We could not include the abnormal CT or MRI findings as a variable in the logistic regression analyses to identify factors associated with the incidence of DNS and unimproved PCD because of the limited amount of data obtained in this study. However, the lower incidence of abnormal CT or MRI findings in the NBO2 group than in the HBO2 group may suggest that the patients in the HBO2 group were more severely affected than those in the NBO2 group. Myocardial injury is also associated with increased long-term mortality after CO poisoning [36]. In the present study, all the data related to myocardial injury, including the creatine kinase MB fraction, troponin T, and ECG abnormalities, tended to be worse in the NBO2 group than in the HBO2 group, although the amount of data was limited (Table 2). These results were inconsistent with the incidence of abnormal in CT or MRI findings. Data, including imaging findings and myocardial injury, were missing for some patients; therefore, it was unclear whether the severity differed between the two groups.
The number of patients treated with mechanical ventilation was significantly higher in the NBO2 group than in the HBO2 group (Table 1) and PaO2 on arrival was significantly lower in the NBO2 group than in the HBO2 group (Table 3). This might have been related to the greater number of patients affected by fire in the NBO2 group (Table 1). Patients affected by fires were more likely to suffer from smoke inhalation, and subsequently require intubation and ventilation because of their low PaO2/fraction of inspiratory oxygen ratio. Intubated patients could not be treated with HBO2 in a monoplace chamber, which may explain the large number of mechanically ventilated patients in the NBO2 group. It was reported that fire causes cyanide poisoning concurrently with CO poisoning [37]. This might also be associated with the higher lactate levels in the NBO2 group. More mechanically ventilated patients in the NBO2 group also experienced longer ICU stays in the NBO2 group. However, a sub-analysis after excluding mechanically ventilated patients yielded the same result, as HBO2 therapy offered no advantage over NBO2 therapy in the prevention of DNS, and multiple HBO2 sessions on day 1 were still associated with a greater incidence of DNS.
Some retrospective studies have found that HBO2 therapy has beneficial effects on the survival rate [38, 39] or activities of daily living (ADL) in patients with CO poisoning [40]. Rose et al. reported that HBO2 therapy was associated with reduced in-hospital mortality and reduced 1-year mortality [38] and Huang et al. reported a lower 4-year mortality rate after treatment for CO poisoning [39]. In the present study, among 311 patients, there were three cases of CPAOA and three in-hospital deaths, but there were no deaths during the follow-up periods, although 41 patients were lost to follow-up. Regarding the effect of HBO2 therapy on the survival rate after CO poisoning, our data did not reveal any evidence to support the previous reports [38, 39] because the follow-up period was only 2 months and 41 patients were lost to follow-up. Nakajima et al. reported that HBO2 therapy was associated with a favorable consciousness level and ADL at discharge in patients with CO poisoning [40]. In the present study, cognitive dysfunction was only checked for 2 months after CO poisoning and there was no significant difference between the NBO2 group and the HBO2 group (Table 3). Therefore, further investigation is needed to explore the long-term beneficial effects of HBO2 therapy.
There were several limitations to the present study. First, it was an observational study. Although there was no significant difference in the severity of poisoning among the subgroups defined by the number of HBO2 sessions received during first 24 h, the more severely affected patients, as assessed by the clinicians, may have received more HBO2 sessions during the first 24 h. Second, the protocols for HBO2 therapy, including the treatment pressure, number of sessions, their timing, and their duration, were not consistent. Third, as mentioned above, an equality of the groups was not maintained in some parts because this was an observational study. Fourth, there might be some selection bias because only 44% of patients in the NBO2 group were transferred to hospitals where HBO2 therapy was available. In those patients, mild cases might have received NBO2 therapy, although the COHb levels in the NBO2 group were not significantly different between patients transferred to institutions that only offered NBO2 therapy (20.9 ± 10.0%) and patients transferred to institutions that also provided HBO2 therapy (17.2 ± 10.1%, P = 0.101). Furthermore, there may have been a selection bias on the part of the EMS, which may have sent less severely affected patients to institutions that only offered NBO2 therapy. Finally, 40% of the patients without DNS were only diagnosed by telephone, so patients with mild symptoms might have been overlooked.
Shortcomings
As mentioned above, there were some selection biases for non-randomized observational studies. In addition, the lack of a protocol for HBO2 treatment made it difficult to interpret results such as dose-response between the number of HBO2 treatments and the incidence of DNS. There were several issues with assessing DNS, including non-blinded evaluators, 13.8% of loss of follow-up, and the possibility of oversight of patients with mild symptoms.
Conclusions
The practical clinical treatment for acute CO poisoning, including HBO2 therapy, varied among the institutions participating in Japan. HBO2 therapy with inconsistent protocols showed no advantages over NBO2 therapy in the prevention of DNS or the improvement in PCD after CO poisoning. Furthermore, multiple HBO2 sessions on the first day of hospitalization were associated with a greater incidence of DNS. Further research is required to clarify the efficacy of HBO2 therapy in preventing DNS after CO poisoning.
Acknowledgments
Members of the COP-J Study Investigators are given below: Yamaguchi University Hospital, Ube (RT, MF, MT, KK), Kameda Medical Center, Kamogawa (SS), Tokai University School of Medicine, Isehara (SW), Hyogo Emergency Medical Center, Kobe (SK), Japanese Red Cross Maebashi Hospital, Maebashi (SS), Chiba University Graduate School of Medicine, Chiba (NH), Tokyo Medical and Dental University, Tokyo (KY), Japan Self Defense Forces Hospital Yokosuka, Yokosuka (KK), Hokkaido University, Sapporo (Tomonao Yoshida), Gunma University Hospital, Maebashi (Hiroaki Matsuoka), Kagawa University, Kagawa (Kenya Kawakita), Saiseikai Kumamoto Hospital, Kumamoto (Tadashi Kikuchi), Hiroshima University Hospital, Hiroshima (Satoshi Yamaga), St.Mary’s Hospital, Kurume (Kazuhito Tamehiro), Tajima Emergency and Critical Care Medical Center, Toyooka Hospital, Toyooka (Osamu Fujisaki), Asahikawa Medical University Hospital, Asahikawa (Yuka Eto), Iwate Medical University, Morioka (Makoto Onodera), Ibaraki Prefectural Central Hospital, Kasama (Yoshimoto Seki), Tokushima Red Cross Hospital, Komatsushima (Yasushi Fukuta), Kumamoto Red Cross Hospital, Kumamoto (Ken Kuwahara), Showa University, Tokyo (Kenichiro Fukuda), Nagano Red Cross Hospital, Nagano (Koji Yamakawa), Osaka University Graduate School of Medicine, Suita (Ryosuke Takegawa), Gifu University Graduate School of Medicine, Gifu (Tomoaki Doi), Yokohama City University Medical Center, Yokohama (Takuma Sakai), St. Luke’s International Hospital, Tokyo (Shutaro Isokawa), Kanmon Medical Center, Shimonoseki (Shinichiro Tanaka), Tokuyama Central Hospital, Shunan (Susumu Yamashita), Kawasaki Medical School, Kurashiki (Yasukazu Shiino), Kumamoto University Hospital, Kumamoto (Tadashi Kaneko), Jichi Medical University, Tochigi (Chikara Yonekawa), National Hospital Organization Kumamoto Medical Center, Kumamoto (Masahiro Harada), Kindai University, Osaka (Takami Nakao), Tamaki Hospital, Hagi (Hideki Tamaki), Almeida Memorial Hospital, Oita (Nobuhiro Inagaki), Kanazawa University Hospital, Kanazawa (Masaki Okajima), Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima (Yasuyuki Kakihana), Aso Iizuka Hospital, Iizuka (Hiroshi Adachi), Nagasaki University Hospital, Nagasaki (Tomohito Hirao), Hiroshima Prefectural Hospital, Hiroshima (Masahiko Iseki), Saiseikai Matsuyama Hospital, Matsuyama (Katsusuke Kusunoki), Yamaguchi Prefectural Grand Medical Center, Hofu (Takeshi Inoue), Kurashiki Central Hospital, Kurashiki (Shinichiro Ienaga), Saiseikai Yamaguchi Hospital, Yamaguchi (Takashi Tamura), St Marianna University School of Medicine, Kawasaki (Nobuhiko Simozawa), Kochi Health Science Center, Kochi (Go Nojima), University Hospital of the Ryukyus, Okinawa (Kiyotaka Kohshi), Kohsei General Hospital, Mihara (Kenjiro Fujiwara), Kizawa Memorial Hospital, Minokamo (Mikito Yamada), Kagawa Rosai Hospital, Marugame (Kimihiro Yoshino), Osaka National Hospital, National Hospital Organization, Osaka (Daikai Sadamitsu), National Hospital Organization Medical Center, Tachikawa (Takashi Kanemura), Jichi Children’s Medical Center Tochigi, Shimotsuke (Hidetaka Iwai), Ina Central Hospital, Ina (Aya Hori).
References
- 1. Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott CG, Clemmer TP, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med. 2002;347: 1057–1067. pmid:12362006
- 2. Annane D, Chadda K, Gajdos P, Jars-Guincestre MC, Chevret S, Raphael JC. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med. 2011;3: 486–492. pmid:21125215
- 3. Raphael JC, Elkharrat D, Jars-Guincestre MC, Chastang C, Chasles V, Vercken JB, et al. Trial of normobaaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet. 1989;2: 414–419. pmid:2569600
- 4. Thom SR, Taber RL, Mendiguren II, Clark JM, Hardy KR, Fisher AB. Delayed neurological sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med. 1995;25: 474–480. pmid:7710151
- 5. Mathieu D, Wattel F, Mathieu-Nolf M, Durak C, Tempe JP, Bouachour G, et al. Randomized prospective study comparing the effect of HBO versus 12 hours NBO in non-comatose CO poisoned patients: results of the interim analysis. Undersea Hyperb Med. 1996;23 Suppl: 7–8.
- 6. Scheinkestel CD, Bailey M, Myles PS, Jones K, Cooper DJ, Millar IL, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomized controlled clinical trial. Med J Aust 1999;170: 203–210. pmid:10092916
- 7. Buckley NA, Juurlink DN, Isbister G, Bennett MH, Lavonas EJ. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev. 2011;2011(4):CD002041. pmid:21491385
- 8. Fujita M, Oda Y, Kaneda K, Kawamura Y, Nakahara T, Todani M, et al. Variability in treatment for carbon monoxide poisoning in Japan—A multicenter retrospective survey. Emerg Med Int. 2018;2018: 2159147. pmid:30627443
- 9. Byrne BT, Lu JJ, Valento M, Bryant SM. Variability in hyperbaric oxygen treatment for acute carbon monoxide poisoning. Undersea Hyperb Med. 2012;39: 627–638. pmid:22530446
- 10. Mutluoglu M, Metin S, Arziman I, Uzun G, Yildiz S. The use of hyperbaric oxygen therapy for carbon monoxide poisoning in Europe. Undersea Hyperb Med. 2016;43: 49–56. pmid:27000013
- 11. Imai Y, Hasegawa K. The Revised Hasegawa’s Dementia Scale (HDS-R)–evaluation of its usefulness as a screening test for dementia. J Hong Kong Coll Psychiatr. 1994;4: 20–24.
- 12. Pepe G, Castelli M, Nazerian P, Vanni S, Del Panta M, Gambassi F, et al. Delayed neuropsychological sequelae after carbon monoxide poisoning: predictive risk factors in the Emergency Department. Scand J Trauma Resusc Emerg Med. 2011;19: 16. pmid:21414211
- 13. Ku HL, Yang KC, Lee YC, Lee MB, Chou YH. Predictors of carbon monoxide poisoning-induced delayed neuropsychological sequelae. Gen Hosp Psychiatry. 2010;32: 310–314. pmid:20430235
- 14. Weaver LK, Valentine KJ, Hopkins RO. Carbon monoxide poisoning: risk factors for cognitive sequelae and the role of hyperbaric oxygen. Am J Respir Crit Care Med. 2007;176: 491–497. pmid:17496229
- 15. Annane D, Chevret S, Jars-Guincestre C, Chillet P, Elkharrat D, Gajdos P, et al. Prognostic factors in unintentional mild carbon monoxide poisoning. Intensive Care Med. 2001;27: 1776–1781. pmid:11810122
- 16. Kim H, Choi S, Park E, Yoon E, Min Y, Lampotang S. Serum markers and development of delayed neuropsychological sequelae after acute carbon monoxide poisoning: anion gap, lactate, osmolarity, S100B protein, and interleukin-6. Clin Exp Emerg Med. 2018;5: 185–191. pmid:30269454
- 17. Jung JW, Lee JH. Serum lactate as a predictor of neurologic outcome in ED patients with acute carbon monoxide poisoning. Am J Emerg Med. 2019;37: 823–827. pmid:30154025
- 18. Thom SR, Mendiguren I, Hardy K, Bolotin T, Fisher D, Nebolon M, et al. Inhibition of human neutrophil beta2-integrin-dependent adherence by hyperbaric O2. Am J Physiol. 1997;272: C770–C777. pmid:9124510
- 19. Birmingham CM, Hoffman RS. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med. 2011;37: 1218. pmid:21350902
- 20. Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med. 2009;360: 1217–1225. pmid:19297574
- 21. Piantadosi CA, Zhang J, Levin ED, Folz RJ, Schmechel DE. Apoptosis and delayed neuronal damage after carbon monoxide poisoning in the rat. Exp Neurol. 1997;147: 103–114. pmid:9294407
- 22. Uemura K, Hoshino S, Uchida K, Tsuruta R, Maekawa T, Yoshida K. Hypothermia attenuates delayed cortical cell death and ROS generation following CO inhalation. Toxicol Lett. 2003;145: 101–106. pmid:14581162
- 23. Thom SR, Bhopale VM, Han ST, Clark JM, Hardy KR. Intravascular neutrophil activation due to carbon monoxide poisoning. Am J Respir Crit Care Med. 2006;174: 1239–1248. pmid:16931637
- 24. Thom SR, Bhopale VM, Fisher D, Zhang J, Gimotty P. Delayed neuropathology after carbon monoxide poisoning is immune-mediated. Proc Natl Acad Sci U S A 2004;101: 13660–13665. pmid:15342916
- 25. Han ST, Bhopale VM, Thom SR. Xanthine oxidoreductase and neurological sequelae of carbon monoxide poisoning. Toxicol Lett. 2007;170: 111–115. pmid:17433579
- 26. Thom SR. Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol. 1993;123: 248–256. pmid:8248932
- 27. Brown SD, Piantadosi CA. Reversal of carbon monoxide-cytochrome c oxidase binding by hyperbaric oxygen in vivo. Adv Exp Med Biol. 1989;248: 747–754. pmid:2551142
- 28. Brown SD, Piantadosi CA. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia. J Clin Invest. 1992;89: 666–672. pmid:1737854
- 29. Oter S, Korkmaz A, Topal T, Ozcan O, Sadir S, Ozler M, et al. Correlation between hyperbaric oxygen exposure pressures and oxidative parameters in rat lung, brain, and erythrocytes. Clin Biochem. 2005;38: 706–711. pmid:15904909
- 30. Korkmaz A, Oter S, Sadir S, Topal T, Uysal B, Ozler M, et al. Exposure time related oxidative action of hyperbaric oxygen in rat brain. Neurochem Res. 2008;33: 160–166. pmid:17710543
- 31. Körpınar Ş, Uzun H. The effects of hyperbaric oxygen at different pressures on oxidative stress and antioxidant status in rats. Medicina (Kaunas). 2019;55: E205. pmid:31137620
- 32. Bader N, Bosy-Westphal A, Koch A, Rimbach G, Weimann A, Poulsen HE, et al. Effect of hyperbaric oxygen and vitamin C and E supplementation on biomarkers of oxidative stress in healthy men. Br J Nutr. 2007;98: 826–833. pmid:17475085
- 33. Wang W, Cheng J, Zhang J, Wang K. Effect of hyperbaric oxygen on neurologic sequelae and all-cause mortality in patients with carbon monoxide poisoning: A meta-analysis of randomized controlled trials. Med Sci Monit. 2019;25: 7684–7693. pmid:31606731
- 34. Jeon SB, Sohn CH, Seo DW, Oh BJ, Lim KS, Kang DW, et al. Acute brain lesions on magnetic resonance imaging and delayed neurological sequelae in carbon monoxide poisoning. JAMA Neurol. 2018;75: 436–443. pmid:29379952
- 35. Du X, Gu H, Hao F, Gao L, Wang J, Sun C, et al. Utility of brain CT for predicting delayed encephalopathy after acute carbon monoxide poisoning. Exp Ther Med. 2019;17: 2682–2688. pmid:30930970
- 36. Henry CR, Satran D, Lindgren B, Adkinson C, Nicholson CI, Henry TD. Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA. 2006;295: 398–402. pmid:16434630
- 37. Kaita Y, Tarui T, Shoji T, Miyauchi H, Yamaguchi Y. Cyanide poisoning is a possible cause of cardiac arrest among fire victims, and empiric antidote treatment may improve outcomes. Am J Emerg Med. 2018;36: 851–853. pmid:29395761
- 38. Rose JJ, Nouraie M, Gauthier MC, Pizon AF, Saul MI, Donahoe MP, et al. Clinical outcomes and mortality impact of hyperbaric oxygen therapy in patients with carbon monoxide poisoning. Crit Care Med. 2018;46: e649–e655. pmid:29629990
- 39. Huang CC, Ho CH, Chen YC, Lin HJ, Hsu CC, Wang JJ, et al. Hyperbaric oxygen therapy is associated with lower short- and long-term mortality in patients with carbon monoxide poisoning. Chest. 2017;152: 943–953. pmid:28427969
- 40. Nakajima M, Aso S, Matsui H, Fushimi K, Yasunaga H. Hyperbaric oxygen therapy and mortality from carbon monoxide poisoning: A nationwide observational study. Am J Emerg Med. 2020;38: 225–230. pmid:30797609